Skip to content

Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation

Fertility Preservation

Whether it is for oncology or personal reasons, fertility preservation allows participants to preserve their oocytes (eggs) at their current age and condition for a better chance of having a baby in the future.

In order to proceed with fertility preservation, participants will need to undergo in vitro fertilization (IVF), which is standard practice, and take stimulation medication to stimulate production of more follicles.

The combination of both Rekovelle and Menopur for fertility preservation may increase ovarian response to stimulation and increase the number of oocytes retrieved to give better chances of embryos once the oocytes will be fertilized.

The goal in this study is to understand the effect of oxydative stress on the quality of oocytes.

For the purpose of the study and to evaluate this connection, serum levels of oxidative stress and cf-DNA in your blood will be measured.

Oocyte quality will also be assessed with Magenta, a prediction tool utilizing artificial intelligence (AI). This method is non-invasive and has no risks on the oocytes.

null

Participation Requirements

  • Sex:

    FEMALE
  • Eligible Ages:

    18 to 37

Participation Criteria

Inclusion Criteria:

- Women 18 to 37 years of age inclusively eligible for fertility preservation for either social or oncology reason

Exclusion Criteria:

* Pregnancy and lactation
* Uncontrolled thyroid or adrenal dysfunction
* Tumours of the hypothalamus or pituitary gland
* Ovarian enlargement not due to polycystic ovarian syndrome
* Gynaecological haemorrhages of unknown aetiology
* Endometriosis stage III/IV
* Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle
* Use of Coenzyme Q10 during the stimulation cycle
* Renal and/or hepatic impairment
* Hypersensitivity to any active ingredient or excipients in follitropin delta and/or HP-hMG

Study Location

Olive Fertility Centre
Olive Fertility Centre
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Amy Malone, RN

[email protected]
604.559.9950
Ottawa Fertility Centre
Ottawa Fertility Centre
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Jennifer McDowall, CCRC

[email protected]
613.686.3378
Clinique Ovo
Clinique Ovo
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Nelly Delouya, RN

[email protected]
514.798.2000
Backup Contact

Marion Vivien, PhD

[email protected]
514.798.2000
Study Sponsored By
Clinique Ovo
Participants Required
More Information
Study ID: NCT05372549